Please use this identifier to cite or link to this item:
|Title:||DEVELOPING THERAPEUTIC BIOIMPLANTS FOR HEMOPHILIA A: BIOSAFETY EVALUATION OF TARGETED TRANSGENE INTEGRATION IN PRIMARY HUMAN UMBILICAL CORD-LINING CELLS USING PHIC31 INTEGRASE AND ZINC FINGER NUCLEASES||Authors:||JAICHANDRAN S/O SIVALINGAM||Keywords:||Gene therapy, hemophilia, zinc finger nuclease, phiC31 integrase, gene targeting||Issue Date:||23-Jul-2013||Citation:||JAICHANDRAN S/O SIVALINGAM (2013-07-23). DEVELOPING THERAPEUTIC BIOIMPLANTS FOR HEMOPHILIA A: BIOSAFETY EVALUATION OF TARGETED TRANSGENE INTEGRATION IN PRIMARY HUMAN UMBILICAL CORD-LINING CELLS USING PHIC31 INTEGRASE AND ZINC FINGER NUCLEASES. ScholarBank@NUS Repository.||Abstract:||Gene and cell-based therapies have been shown to successfully treat genetic disorders. However, the inability of current gene therapy vectors to direct transgene integrations precisely into safe genomic sites has been associated with oncogenic mutations and fatal leukemias. A major challenge is devising gene transfer techniques that are efficacious and result in durable transgene expression but are not mutagenic. Using hemophilia A as a disease model, we evaluated the potential of phiC31 integrase and zinc-finger nucleases (ZFNs) to modify primary human umbilical cord-lining epithelial cells (CLECs) to stably integrate and express a factor VIII transgene, with the ultimate aim of developing autologous treatment for pediatric patients with hemophilia A. Transgene integration resulted in durable FVIII secretion. Transgenic CLECs were evaluated by transcriptome and genome copy number profiling, deep-sequencing of predicted off-target sites, spectral karyotyping and in vivo tumorigenicity in immunocompromised mice to gauge their biosafety.||URI:||http://scholarbank.nus.edu.sg/handle/10635/49154|
|Appears in Collections:||Ph.D Theses (Open)|
Show full item record
Files in This Item:
|Jaichandran S Thesis corrected 111213 pm.pdf||12.45 MB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.